iBio, Inc. announced the expansion of its AI-powered technology stack with the launch of ShieldTx, a patent-pending antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue. By adding ShieldTx to its Drug Discovery Platform, iBio uniquely integrates antibody engineering and masking in one accelerated process to potentially overcome the challenges of complex targets, safety, and developability in next-generation antibody discovery and development. The Company used ShieldTx to develop masks for its MUC16-targeted bispecific antibody (Ab) candidates, which were previously developed using iBio?s patented Epitope Steering and EngageTx? AI Platforms. MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and pancreatic cancers.

In an in vitro laboratory setting, iBio?s specially designed MUC16 bispecific Abs were deactivated and then reactivated, demonstrating successful application of the ShieldTx technology.